The CEO of Cambridge gene therapy firm Voyager Therapeutics has purchased an $8 million penthouse condominium at the luxury Millennium Tower in Boston, according to a Suffolk County deed.
Steven M. Paul acquired a 56th floor unit, which includes two reserved parking spots, according to the Nov. 22 deed.
With the purchase, Paul will join a number of prominent local executives at the brand-new tower in Boston’s Downtown Crossing, including Dell founder and CEO Michael Dell, who recently bought a $10.9 million penthouse condo.
Voyager (Nasdaq: VYGR) was launched in February 2014 and went public in November 2015 with a $70 million offering. The company is part of a new wave of biotechs in Massachusetts that are working on treatments that involve replacing a faulty gene with a corrected one.
Paul joined Voyager as CEO in September 2014, after serving as the head of research and development at Eli Lilly. Paul currently also serves on the boards of Cambridge-based biotechs Alnylam Pharmaceuticals and Sage Therapeutics.
On Dec. 7, Voyager reported positive results from an early-stage study of a Parkinson’s treatment, sending shares of the company soaring. Parkinson’s kills off important nerve cells that generate dopamine, resulting in the loss of movement and coordination. Voyager’s treatment involves drilling a hole into a patient’s skull and infusing a gene that helps to produce dopamine.
In an interview at the time, Paul said that Voyager has about 75 employees but is looking to grow to more than 100 by the middle of 2017. The company has a manufacturing partnership with MassBiologics at the University of Massachusetts Medical School.
No comments:
Post a Comment